Sulfanilamide
Sulfanilamide is the prototype sulfonamide antibiotic and the parent compound from which all sulfonamide drugs are derived, used topically for vaginal candidiasis and bacterial vaginitis and historically as a systemic antibacterial before more effective agents were available. It acts as a structural analog of para-aminobenzoic acid (PABA), competitively inhibiting dihydropteroate synthase and blocking bacterial folic acid biosynthesis. It is also the precursor of carbonic anhydrase inhibitors and thiazide diuretics through chemical modification.
Peso Molecular
172,2100 g/mol
LogP
-0,60
TPSA
94,60 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
Nc1ccc(S(N)(=O)=O)cc1
InChI
InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
Molecular Formula
C6H8N2O2S
HBD / HBA
2 / 4
Ligações Rotacionáveis
1
Átomos Pesados
11
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Sulfanilamide is the prototype sulfonamide antibiotic and the parent compound from which all sulfonamide drugs are derived, used topically for vaginal candidiasis and bacterial vaginitis and historically as a systemic antibacterial before more effective agents were available. It acts as a structural analog of para-aminobenzoic acid (PABA), competitively inhibiting dihydropteroate synthase and blocking bacterial folic acid biosynthesis. It is also the precursor of carbonic anhydrase inhibitors and thiazide diuretics through chemical modification.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Sulfanilamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL21. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5333. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sulfanilamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sulfanilamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sulfanilamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sulfanilamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sulfanilamide"></drugfyi-drug>